In future experiments, using a xenograft breast cancer syngeneic mouse model with an intact immune system to test how the alteration of TWIST1 expression and/or anti-PD-L1 therapy will affect tumor growth, CD8+ T-cell exhaustion, and immunotherapy efficacy will further confirm the role of TWIST1 in breast cancer immune evasion. Here, CD274 is linked to breast cancer.